论文部分内容阅读
一项包括600名患者的三期临床试验的结果表明,与单独化疗相比,曲妥珠单抗联合化疗能够使人表皮生长因子受体2阳性(HER2)的晚期胃癌或食管胃连接部癌症患者的死亡率降低26%。ToGA研究(曲妥珠单抗用于治疗胃癌)是一项多中心开放标签研究,以评估对HER2过度表达的晚期胃癌和胃食管连接部癌症患者在标准化疗之外加用曲妥珠单抗的安全性和有效性。所有584名患者均给予化
A phase III trial of 600 patients showed that trastuzumab combined with chemotherapy resulted in advanced gastric cancer or esophagogastric junction cancers in human epidermal growth factor receptor 2 (HER2) tumors compared with chemotherapy alone The patient’s mortality rate decreased by 26%. The ToGA study (trastuzumab for the treatment of gastric cancer) is a multicenter open-label study to assess the efficacy of trastuzumab in addition to standard chemotherapy in patients with advanced gastric and gastroesophageal junction cancer over-expressing HER2 Safety and effectiveness. All 584 patients were given chemotherapy